Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study by Pulvirenti, Federica et al.
ORIGINAL ARTICLE
Health-Related Quality of Life in Patients with CVID Under Different
Schedules of Immunoglobulin Administration: Prospective Multicenter
Study
Federica Pulvirenti1 & Francesco Cinetto2 & Antonio Pecoraro3 & Maria Carrabba4 & Ludovica Crescenzi3 &
Raffaella Neri2 & Livia Bonanni1 & Giovanna Fabio4 & Carlo Agostini2 & Giuseppe Spadaro3 & Stefano Tabolli1 &
Albert Farrugia5 & Isabella Quinti1 & Cinzia Milito1
Received: 6 August 2018 /Accepted: 4 January 2019 /Published online: 15 January 2019
Abstract
Objective We assessed the health-related quality of life (HRQoL) in CVID adults receiving different schedules of immunoglob-
ulin replacement therapy (IgRT) by intravenous (IVIG), subcutaneous (SCIG), and facilitated (fSCIG) preparations. For these
patients, IgRT schedule was chosen after a period focused on identifying the most suitable individual option.
Methods Three hundred twenty-seven participants were enrolled in a prospective, observational, 18-month study. Participants
received IgRT for at least 2 years. The first 6 months were devoted to the educational process during which the choices related to
IgRTwere regularly re-assessed, and the shift to alternative regimen was permitted. During the following 12months, clinical data
were prospectively collected, and only patients who did not further modify their IgRT schedule were included in the analysis of
HRQoL measured by CVID_QoL, a specific instrument, and by GHQ-12, a tool to assess minor psychiatric nonpsychotic
disorders.
Results Three hundred four patients were included in the analysis. CVID_QoL global score and its dimensions (emotional
functioning, relational functioning, gastrointestinal symptoms) were similar in IVIG, SCIG, and fSCIG recipients. Patients
receiving IgRT by different routes of administration reported similar capacity to make long-term plans, discomfort due to therapy,
and concern to run out of medications. Multivariate analysis revealed the GHQ-12 status, but not the IgRT mode of administra-
tion, as the major factor impacting on treatment-related QoL items, and a significant impact of age on discomfort related to IgRT.
Conclusions IgRT schedules do not impact the HRQoL in CVID if the treatment is established after an extensive educational
period focused on individualizing the best therapeutic regimen.
Keywords Health-related quality of life . common variable immunodeficiency . immunoglobulin replacement treatment .
CVID_QoL . patient empowerment
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SCIG Subcutaneous immunoglobulins
fSCIG facilitated subcutaneous immunoglobulins
IgG TL Immunoglobulin G trough levels
CVID_QoL Common Variable Immune Deficiencies
Quality of Life questionnaire
EF Emotional functioning
RF Relational functioning
GSS Gastrointestinal and skin symptoms
COPD Chronic obstructive pulmonary disease
Introduction
Common variable immune deficiencies (CVID) are a group of
diseases whose complexity in clinical presentation and treat-
ment poses difficulties in management [1]. Significant prog-
ress has been made over the past few decades in awareness,
early diagnosis, and therapeutic options, including immuno-
globulin replacement therapy (IgRT), which have led to a
profound change in the approach to affected patients [2, 3].
The advent of intravenously administered polyvalent immu-
noglobulin preparations (IVIG) in the 1980s dramatically de-
creased morbidity and mortality and replacement therapy is
universally considered to be life-saving. Subsequently, the
introduction of further therapeutic options, including the sub-
cutaneous route of Ig administration (SCIG), which may also
be facilitated by human recombinant hyaluronidase (fSCIG),
and the availability of formulations containing immunoglob-
ulin at different concentrations have led to changes in the
schedule of administration [4]. In addition, the increased clin-
ical demand for the products’ range of indications has fueled
an increased requirement for plasma fractionation, leading to
an expansion of the plasma donor population and has en-
hanced methods to improve IgG recovery [5]. Since CVID
patients require therapy for life, the acceptability of the differ-
ent schedules and setting for Ig administration are now con-
sidered important instruments to achieve adherence to treat-
ment and in increasing health-related quality of life (HRQoL)
in these patients [6]. Studies indicate a heterogeneity in pa-
tients’ attitudes to treatment, in particular to the role of IgRT.
While a cohort of European patients with markedly different
levels of access to IgRT showed similar HRQoL [6], a similar
US-based assessment indicated that a regular access to therapy
is beneficial in perceived health [7]. We have previously
shown that such an HRQoL elicitation did not reveal any
influence of Ig administration schedule in an Italian cohort,
using generic and disease-specific instruments [8–10]. As
with other chronic conditions, treatment of patients living with
CVID could impose demands on daily life to plan and self-
care management, as a result of the need to comply with com-
plex therapeutic schedules, while balancing family or job
commitments. This can result in a Bburden of treatment^
[11, 12]. Hence, the importance of defining a tailored
immunoglobulin treatment plan for each patient’s situation
has been shown [13–15], with clear implications on patient
well-being [16, 17]. Our own work indicates that patients with
CVID manifest substantial restrictions and poor HRQoL,
which worsen over the time, mainly due to CVID-associated
clinical conditions [8–10].
In order to identify problems related to IgRT route of ad-
ministration, which may impact on the HRQoL of patients, we
designed and carried out a prospective observational study on
the HRQoL of adult patients with CVID. This investigation
followed a long period of patients’ education and training
aimed to establish the best treatment option. HRQoL was
assessed by a recently validated new instrument: the
CVID_QoL questionnaires [10], together with the GHQ-12,
a tool to detect nonpsychotic, minor psychiatric disorders,
such as depression and anxiety [18]. The study sought to gen-
erate information to help health care professionals to under-
stand factors that may impact on patient’s everyday life and
possibly contribute to maximizing patient empowerment and
satisfaction with care, while minimizing the impact of illness.
Methods
Population Analyzed
Eligible patients were adults aged > 18 years with a diagnosis
of CVID (http://esid.org/Working-Parties/Registry/Diagnosis-
criteria) under IgRT for at least 2 years before enrollment. All
patients were regularly followed by university hospital care
centers for adult primary immune deficiencies in Rome,
Naples, Padua, and Milan. Exclusion criteria included the
following: inability or unwillingness to provide written
informed consent and refusal to complete the HRQoL
questionnaires. The Ethical Board of the Sapienza,
University of Rome approved this study. The study was
performed in accordance with the Good Clinical Practice
guidelines, the International Conference on Harmonization
guidelines, and the most recent version of the Declaration of
Helsinki.
Study Design
Prospective, observational, multicenter, 18-month study
(Flow Chart, Fig. 1). The study was designed to address the
impact of the route of IgRT administration on CVID HRQoL.
To assess this need, all CVID patients attending the participat-
ing care centers and fulfilling the inclusion criteria were invit-
ed to participate in the study. At enrollment (T0), patients
signed the written informed consent. Afterward, the first
6 months of the study (Bequilibration^) was devoted to the
education and training of patients. The aim of the education
process was to discuss the possible choices related to IgRT
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administration, including setting, route, intervals, possible ad-
verse reactions, and participant lifestyle pattern. This process
was intended to optimize the IgRT treatment program accord-
ing to the participants’ individual needs, before assessing the
HRQoL. During the Bequilibration,^ physicians performed at
least three clinical visits to re-evaluate and possibly to modify
the choice of IgRT based on individual preferences, tolerabil-
ity, and acceptability. All patients continued to be monitored
for their clinical status according to the Italian guidelines [19].
Patients who changed their immunoglobulin administration
regimen were trained by expert nurses. Patients who shifted
to fSCIG/SCIG (or their caregivers) self-administered Ig un-
der nurse supervision until their ability was considered satis-
factory both from themselves and nurses (at least three set-
tings). At the end of the 6-month period (T1), patients were
included in a 12-month observational study on their HRQoL.
At T1, a set of variables was recorded for each patient includ-
ing: gender, date of birth, date of CVID diagnosis, Ig serum
levels at diagnosis, and IgG trough levels (TL). At the end of
the observational period (T2), patients completed the
CVID_QoL questionnaire, a disease-specific tool recently val-
idated to assess HRQoL in CVID [10]. On the same day,
patients completed the GHQ-12 questionnaire, a screening
device for the identification of minor psychiatric disorders,
such as anxiety and depression [18]. During the observational
period, participants visited to the clinics every 3 months, and
nomedical procedures were performed outside those provided
for individual care management. Patients who changed their
IgRT schedule during T1–T2 were excluded by the analysis.
At the end of the observational period (T2), clinical, immuno-
logical, and treatment data related to the period T1–T2 were
collected from the medical records, including adherence.
Adherence was defined as being able to maintain the
established dose and interval of IgRT for more than 90% of
administrations.
Questionnaires
The CVID_QoL is a self-administered questionnaire devel-
oped and validated in Italy in 2016 and translated into US
English [10]. Study on translation and cross-cultural valida-
tion are currently ongoing in several countries. The instrument
includes 32 items in a Likert-type or forced-choice format and
measures health on three multi-item dimensions: emotional
functioning (EF), relational functioning (RF), and gastrointes-
tinal and skin symptoms (GSS). It includes also a summary
measure named global CVID_QoL. The EF dimension in-
cludes 19 items on patient feelings, on difficulties related to
Fig. 1 Study design flow-chart.
Abbreviation: CVID_QoL,
common variable
immunodeficiency quality of life
questionnaire; fSCIG, facilitated
subcutaneous immunoglobulin;
GHQ-12 GHQ-12, questionnaire;
IVIG, intravenously-administered
immunoglobulins; IVIG + SCIG,
immunoglobulin replacement
therapy by combined intravenous
and subcutaneous route of
administration; IgRT,
immunoglobulin replacement
treatment; SCIG, subcutaneous
Immunoglobulins
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CVID manifestations, on Ig replacement treatment and rela-
tionships with other patients, and on fears concerning evolu-
tion of disease or adverse reaction to treatments. The RF di-
mension includes nine items on patients’ relationship with
relatives and not-affected people; gastrointestinal and skin
symptom (GSS) domain includes four items on complications
related to gastrointestinal manifestation or skin disease. The
content of the CVID_QoL questionnaire is summarized in
Supplementary Table 1. Response options are formulated
using a 5-point scale, with 0 = Bnever^ and 4 = Balways,^with
higher values indicating increasing disability. The CVID_QoL
global score and scores for each dimension are defined as the
sum of all scores of each item transformed as a percentage of
the maximum possible score. Additionally, to better evaluate
the impact of IgRT on HRQoL, we analyzed the score of
single questions (Q) possibly related to IgRT: Q.5; difficulties
tomake long-term plans; Q.9: discomfort/pain on joints; Q.11:
being afraid to run out of medications; Q.12: being concerned
on adverse events to Ig treatment; Q.15: feeling less indepen-
dent than usual; Q.24: being bothered by Ig treatment; Q31:
being troubled by relationships with other CVID patients;
Q32: feeling tired.
The GHQ-12 [18] is a self-administered, 12-items ques-
tionnaire, designed to measure psychological distress and to
detect current nonpsychotic, psychiatric disorders, such as de-
pression and anxiety. Answers are given on a 4-point scale.
When scored with the binary method (0–0–1–1), the GHQ-12
can be used as a screening tool yielding final scores that range
from 0 to 12. Operationally, patients scoring 4 or more were
considered as BGHQ-positive (GHQ+)^/at risk of anxiety and
depression.
Statistical Analysis
Demographics of the CVID database are summarized with
descriptive statistics. Sociodemographic, immunological,
and clinical variables were compared between patients receiv-
ing different immunoglobulin treatments. For repeated mea-
sures (i.e., IgG through level), the individual mean value was
calculated. We first conducted a univariate analysis to assess
the impact of variable of interest related to the eight questions
of CVID_QoL on IgRT. The χ2 test was used for categorical
variables, and the t test was used for continuous variables. A
multiple linear regression model was used to simultaneously
evaluate the impact of selected variables on the eight questions
of CVID_QoL related to IgRT. The selection of these vari-
ables was based on the underlying conceptual framework than
on pure statistical significance and included age, sex, route of
IgRT administration, GHQ status, COPD, enteropathy, occu-
pation, and education level. The standardized beta coefficient
was used to compare the magnitude of association. The statis-
tical significance was set at the conventional level of p < 0.01
to reduce the chance of false positives. Statistical Package for
Social Sciences version 15 (SPSS Inc., 233 South Wacker
Drive, 11th Floor, Chicago) was used for the analysis.
Results
Patient Population and Immunoglobulin
Administration
As shown in Fig. 1, 355 CVID patients were assessed for
eligibility and 28 were excluded (21 for not meeting inclusion
criteria and seven for refusal to participate). Three-hundred
twenty-seven participants were enrolled in the educational/
training 6 months. Forty-five subjects decided together with
their doctor to change the mode of administration during the
education period: 29% participants shifted from IVIG to
SCIG, 27% from IVIG to fSCIG, 20% from fSCIG to IVIG,
11% from SCIG to fSCIG, and 13% from SCIG to IVIG. In
the following 12 months (observational study), 23 patients
decided to further modify the IgRT schedule defined and then
they were excluded from the analysis (reasons for changing
are listed in Supplementary Table 2).
Three-hundred and four CVID patients (mean age =
47 years, range = 18–82, 1:1 male to female ratio) concluded
the 12-month observational period and completed the
CVID_QoL and the GHQ-12 questionnaires. The largest
group of participants included patients under IVIG (206 sub-
jects; 67.7%), followed by patients receiving SCIG (59 sub-
jects; 19.4%) and fSCIG (33 subjects; 10.0%). Six patients
(1.9%) received replacement therapy by SCIG plus IVIG
(combined IgRT), because they were unable in the past to
maintain an acceptable IgG trough level (> 500 mg/dL) by
other schedules of administration (Fig. 1).
At T1, groups under fSCIG, SCIG, and IVIG were compa-
rable for IgG trough levels and for length of CVID disease.
Patients receiving IVIG were older than those receiving
fSCIG (49.2 ± 16.1 years vs 40.3 ± 11.2 years, d = 0.64, p =
0.006). Compared to patients under fSCIG and SCIG, patients
receiving IVIG had lower IgG serum levels at diagnosis, IgA
serum levels, and frequencies of switched memory B cells
(CD19+CD27+IgM−IgD−), even if these differences were not
statistically significant (Table 1).
At T2, groups under fSCIG, SCIG, and IVIG were compa-
rable for the monthly cumulative dose of immunoglobulins
administered, IgG trough levels, and for antibiotic prophylaxis
usage (Table 2). As expected, the average number of monthly
IgG administrations was different between groups (SCIG vs
fSCIG d = 1.72, p < 0.001, SCIG vs IVIG d = 1.81, p < 0.001).
There was no difference in the adherence to treatment between
patients receiving fSCIG (94%), SCIG (92%), and IVIG
(94%). Reasons of poor adherence were all related to difficul-
t ies to maintain the established interval between
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administrations: fSCIG (2/33), SCIG (5/59), IVIG (12/206),
and combined routes of Ig treatment (1/6).
CVID-Associated Morbidities
Figure 2 shows data on CVID-associated clinical conditions in
the 304 patients, grouped according to the route of Ig replace-
ment. Patients on fSCIG had the lowest frequency of associ-
ated conditions. However, significant differences were not
found between groups (Fig. 2a). The group under combined
therapy displayed a more severe phenotype (high rate of
chronic obstructive pulmonary disease (COPD), bronchiecta-
sis, and autoimmune diseases) and the highest number of
CVID-complications (3.33 ± 1.50, p = 0.006, Fig. 2b).
Table 3 shows the rate of infections and the number of
hospitalizations recorded among participants during the
12 months of observational period. No difference was found
among groups in the number of cumulative episodes of diar-
rhea, acute sinusitis, bronchitis, otitis, and pneumonia. No
difference was further found in the number of hospitalizations
for any cause among groups. A further analysis was carried
out within patients who were treated with IVIG preparations
Table 1 Characteristics of CVID patients by type of immunoglobulin treatment at T1
fSCIG
n = 33
SCIG
n = 59
IVIG
n = 206
SCIG + IVIG
n = 6
Age (years), mean (SD) 40.3 (11.2)c 45.2 (13.1) 49.2 (16.1)a 39.2 (13.1)
Sex (females), n (%) 11.5(33.1) 26.1 (44.2) 113.2 (55.2) 4.5 (67.2)
Occupation (employed), n (%) 25 (75) 34 (57) 99 (48) 3 (50)
Education (≥ high school), n (%) 30 (90) 48 (81) 150 (73) 5 (83)
Time (years) from PID diagnosis, mean (SD) 11.2 (9.2) 9.0 (7.1)d 12.3 (11.1) 19.1 (11.0)b
Ig serum levels at diagnosis:
- IgG (mg/dL), mean (SD) 326.3 (183.5) 313.3 (161.2) 246.5 (179.2) 160.2 (186.3)
- IgM (mg/dL), mean (SD) 23.2 (21.2) 27.2 (24.6) 26.1 (38.6) 5.2 (5.1)
- IgA (mg/dL), mean (SD) 39.1 (52.3) 28.2 (33.5) 22.3 (58.3) 18.2 (26.2)
IgG trough serum levels (mg/dL), mean (SD) 713.3 (115.1) 745.0 (109.2)d 725.1 (180.2) 600.5 (122.3)b
CD3+ CD4+/mm3, mean (SD) 785.3 (542.1) 740 (381) 624.1 (343.2) 935.7 (763.1)
CD19+ (%), mean (SD) 8.6 (8.3) 12 (17) 13.1 (23.2) 6.1 (1.0)
CD19+ CD27+ IgM− IgD− (%), mean (SD) 7.8 (14.7) 7 (10) 6.1 (14.2) 2.1 (3.2)
a p < 0.01 in comparison to fSCIG group
b p < 0.01 in comparison to SCIG group
c p < 0.01 in comparison to IVIG group
d p < 0.01 in comparison to IVIG + SCIG group
Table 2 Data of CVID patients at T2
fSCIG
n = 33
SCIG
n = 59
IVIG
n = 206
SCIG + IVIG
n = 6
IgG trough serum levels (mg/dL), mean (SD) 723.5 (143.1) 797 (159) 756.2 (214.2) 607.3 (162.1)
IgM serum levels (mg/dL), mean (SD) 28.6 (25.2) 23 (26) 30.1 (51.2) 10.5 (9.5)
IgA serum levels (mg/dL), mean (SD) 40.2 (58.2) 30 (45) 24.1 (63.2) 12.3 (24.4)
Cumulative monthly Ig dose (mg/kg), mean (SD) 317.8 (120.3)d 359.0 (152.5) 351.5 (148.6) 490.2 (238.1)a
Number of monthly administrations mean (SD) 2.1 (1.0)b 4.1 (1.3)a,c 2.0 (1.0)b 4.2 (2.5)
Antibiotic prophylaxis, n (%) 4 (12.1) 9 (15.2) 23 (11.5) 2 (33.2)
Adherent to treatment, n (%) 31 (93.9) 54 (91.5) 194 (94.4) 5 (83.3)
a p < 0.01 in comparison to fSCIG group
b p < 0.01 in comparison to SCIG group
c p < 0.01 in comparison to IVIG group
d p < 0.01 in comparison to IVIG + SCIG group
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containing 5 (5%) or 10 (10%) grams/dL. Groups under IVIG
5 and 10% were comparable by demographics, IgG cumula-
tive monthly dosage, and CVID-associated conditions. No
difference in the number of infectious episodes was observed
between patients under the two-treatment concentration
(Supplementary Table 3).
Quality of Life
HRQoL was evaluated by the generic GHQ-12 question-
naire [18] and by the disease-specific CVID_QoL ques-
tionnaire [10] at the end of the observational period.
Nearly half (46%) of participants had a GHQ-positive sta-
tus (Fig. 3a). Patients under fSCIG less likely had a GHQ-
positive status in comparison to patients receiving IVIG
(p = 0.01; OR 3.2, 95% CI 1.3–7.7) and SCIG (p = 0.01;
OR 3.0, 95% CI 1.1 to 8.4). Moreover, in the IVIG group,
no difference was recorded between patients receiving 5 or
10% preparations (Supplementary Table 3). No significant
differences were found in CVID_QoL global scores and in
its dimensions EF, RF, and GSS between groups under
different Ig route of administration (Fig. 3a). The univari-
ate analysis of single questions related to immunoglobulins
treatment (Fig. 3b) showed no difference between patients
belonging to the fSCIG, SCIG, and IVIG groups in terms
of difficulties to make long-term plans (Q.5), being afraid
to run out of medications (Q.11), being concerned on ad-
verse events to Ig treatment (Q.12), nor being bothered by
Ig treatment (Q.24). Participants under fSCIG reported to
feel Bless independent than usual less frequently^ (Q.15) in
comparison to those under SCIG (d = 0.55, p = 0.01) or
under IVIG (d = 0.55, p = 0.006). Moreover, CVID under
IVIG reported significantly higher score (greater difficul-
ties) on discomfort/pain on joints (Q.9, d = 0.60, p = 0.002)
and on being troubled by relationships with other CVID
patients (Q.31, d = 0.28, p = 0.004) in comparison to pa-
tients receiving fSCIG. Notably, CVID receiving both
SCIG and IVIG (combined) reported a lower score related
Fig. 2 CVID-related clinical conditions (panel a) and mean number of
co-morbidities (panel b) observed in CVID grouped according to their
IgRT during the observational time. p values by the t test. **p ≤ 0.01.
Abbreviation: CVID, common variable immunodeficiency; COPD,
chronic obstructive pulmonary diseases; IVIG, intravenously-
administered immunoglobulins; SCIG, subcutaneous Immunoglobulins;
fSCIG, facilitated subcutaneous immunoglobulin; IVIG + SCIG,
immunoglobulin replacement therapy by combined intravenous and
subcutaneous route of administration
Table 3 Number of acute infectious episodes and hospital admission
FSCIG
n = 33
SCIG
n = 59
IVIG
n = 206
SCIG + IVIG
n = 6
Diarrhea, episodes-year, mean (SD) 4.1 (2.7) 3.2 (3.1) 3.3 (2.8) 4.7 (3.9)
Sinusitis, episodes-year, mean (SD) 1.6 (1.6) 1.6 (1.6) 1.7 (1.6) 2.7 (1.8)
Bronchitis, episodes-year, mean (SD) 1.3 (1.5) 1.4 (1.5) 1.3 (1.5) 1.7 (1.6)
Otitis, episodes-year, mean (SD) 0.3 (0.8) 0.3 (0.8) 0.4 (1.0) 0.3 (0.8)
Patients with pneumonia, n (%) 6 (18.8) 5 (8.9) 30 (14.9) 1 (16.7)
All infections requiring treatment episodes-year, mean (SD) 4.4 (5.2)§ 3.9 (3.8) 3.8 (4.0) 9.0 (6.1)§
Hospital admission (all causes), n (%) 2 (6.1) 7 (11.9) 15 (7.3) 1 (16.7)
§ p < 0.01, comparison between fSCIG group and IVIG + SCIG group
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to their concern for adverse events due to replacement
therapy (Q.12) in comparison to fSCIG (d = 0.75, p =
0.01) and SCIG group (d = 0.93, p = 0.01). Univariate anal-
ysis revealed the GHQ-positive status as strongly
(p < 0.0001) linked to all IgRT-related items, except for
Q.11 (Bto be afraid to run out of medications,^ Table 4).
BDifficulties to make long-term plans^ (Q.5) were associ-
ated to female gender, COPD, low educational level, and
unemployed status; similarly, older patients (≥ 40 years),
females, with COPD, and unemployed reported Bto feel
more frequently less independent than usual^ (Q.15).
Higher score on Bdiscomfort/pain on joints^ were recorded
in older, less educated, unemployed participants and fe-
males. Older patients were more likely to be Btroubled by
relationships with other CVID patients.^ Females, unem-
ployed, and COPD patients reported to Bfeel more fre-
quently tired^ (Q.32) (Table 4). Multivariate analysis con-
firmed the lack of impact of the route of IgRT administra-
tion and revealed a major role of GHQ-positive status on
all the eight items. The analysis also revealed a significant
impact of age on Bdiscomfort/pain on joints^ (Q.9) and on
being Bbothered by immunoglobulins^ (Q.24) (Table 5).
Discussion
This observational study on adult CVID patients receiving
IgRT in a real-life setting indicates that the route of Ig
administration does not impact on the HRQoL if the treat-
ment choice has been shared by patients and their physi-
cians. Here, the best IgRT option has been established
through a 6-month educative process, during which the
participants’ lifestyle pattern, attitude, habits, and Ig tol-
erability were reviewed and discussed. This procedure
was aimed at identifying new needs/product tolerability,
verifying the initial choice of IgRT, and guiding towards
compliance and a good adherence to treatment.
In our setting, recipients of distinct IgRT routes had similar
scores in all the CVID_QoL domains, including the summary
measure and its three dimensions. Participants receiving
IVIG, SCIG, and fSCIG further reported similar capacity to
make long-term plans, similar distress due to therapy, and
similar concern to run out of medications and to experience
adverse events. CVID patients receiving IVIG more frequent-
ly reported Bdiscomfort/pain on joints^ and to Bfeel less
independent,^ conditions that appeared to be mainly related
Fig. 3 GHQ status and CVID_QoL score. Proportion of GHQ-12-
positive participants and global. EF, RF, and GSS scores (panel a)
recorded for CVID grouped according to the route of IgG replacement
treatment. CVID_QoL global. EF, RF, and GSS are expressed as
percentage of the respective total score with higher values indicating
increasing disability. Scores of eight single items of the CVID_QoL
related to the immunoglobulin treatment (panel b). p values by the t
test. **p ≤ 0.01. Abbreviation: CVID_QoL, common variable
immunodeficiency quality of life questionnaire; EF, emotional
functioning; IVIG, intravenously administered immunoglobulins;
fSCIG, facilitated subcutaneous immunoglobulin; GHQ-12, GHQ-12
questionnaire; GSS, gastrointestinal and skin symptoms; IgRT,
immunoglobulin replacement treatment; IVIG + SCIG, immunoglobulin
replacement therapy by combined intravenous and subcutaneous route of
administration; Q, question; RF, relational functioning; SCIG,
subcutaneous immunoglobulins
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to underlying anxiety and/or depression and to the older age,
as revealed by multivariate analysis. Moreover, no differences
in efficacy, tolerability, and HRQoL scores were found be-
tween patients receiving intravenous immunoglobulins at dif-
ferent concentrations. This lack of impact of the IgRT route
on HRQoL in adult CVID further emphasizes the need of
empowering patients in the management of their life-long
disease and to focus on their psychological status [17].
The use of HRQoL tools helps to address issues related to
the influence of disease and therapy from the patients’ per-
spective, following the principle of the patient-centered health
care system [20]. Using HRQoL generic instruments in
CVID, our group and others have shown that patients with
CVID experience significantly lower general health and in-
creased physical and social activity limitation [6, 8, 21–23]
and that HRQoL outcome measures could help to evaluate
Table 5 Impact of patients’ characteristics on CVID_QoL items related
to immunoglobulins treatment by multiple linear regression
Standardized beta p value
Q5. I had to give up making long-term plans
Route of IgRT − 0.082 0.202
GHQ positive status 0.297 < 0.0001
Age 0.033 0.613
Sex 0.101 0.121
COPD 0.068 0.276
Enteropathy 0.111 0.075
Education − 0.103 0.132
Occupation − 0.063 0.366
Q9. I had discomfort and/or pain in my joints
Route of IgRT 0.075 0.241
GHQ positive status 0.196 0.003
Age 0.189 0.005
Sex 0.045 0.492
COPD 0.022 0.729
Enteropathy 0.050 0.421
Education − 0.115 0.094
Occupation − 0.072 0.308
Q11. I was afraid I would run out of medication
Route of IgRT − 0.073 0.289
GHQ positive status 0.16 0.022
Age 0.075 0.289
Sex − 0.032 0.649
COPD 0.135 0.045
Enteropathy − 0.036 0.591
Education 0.001 0.994
Occupation − 0.034 0.653
Q12. I was afraid of adverse reaction to Ig therapy
Route of IgRT − 0.107 0.115
GHQ positive status 0.204 0.004
Age 0.012 0.861
Sex − 0.044 0.528
COPD 0.007 0.922
Enteropathy 0.038 0.568
Education − 0.133 0.067
Occupation − 0.051 0.494
Q15. I felt less independent than usual
Route of IgRT − 0.042 0.504
GHQ positive status 0.329 < 0.0001
Age 0.134 0.042
Sex 0.065 0.314
COPD 0.074 0.237
Enteropathy 0.059 0.34
Education 0.018 0.789
Occupation − 0.077 0.272
Table 5 (continued)
Standardized beta p value
Q24. Ig therapy bothered me
Route of IgRT − 0.13 0.047
GHQ positive status 0.301 < 0.0001
Age − 0.191 0.005
Sex 0.042 0.529
COPD 0.024 0.708
Enteropathy 0.063 0.325
Education − 0.108 0.121
Occupation − 0.044 0.534
Q31. I felt troubled by relationship with other patients
Route of IgRT 0.045 0.506
GHQ positive status 0.176 0.012
Age 0.07 0.320
Sex 0.033 0.634
COPD 0.02 0.762
Enteropathy 0.005 0.942
Education − 0.085 0.243
Occupation 0.022 0.774
Q32. I felt tired
Route of IgRT − 0.034 0.583
GHQ positive status 0.412 0.0001
Age − 0.011 0.868
Sex 0.095 0.134
COPD 0.124 0.042
Enteropathy − 0.005 0.939
Education − 0.025 0.702
Occupation − 0.027 0.693
Abbreviation: COPD, chronic obstructive pulmonary disease; GHQ,
General Health Questionnaire; IgRT, immunoglobulin replacement treat-
ment; Q, question (number)
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disease progression over time and could predict morbidity and
mortality in subjects with CVID [9].
The use of disease-specific tools is desirable to provide a
more accurate picture of the burden of disease [10, 24, 25].
The CVID_QoL questionnaire is the first specific instrument
for CVID [10], and in addition to the burden of disease due to
the complex clinical picture [26], the questionnaire analyzes
also the experience of the so called Bburden of treatment^ [11,
27]. In fact, the burden of treatment has also an impact on the
needs of everyday life, in planning and managing one’s self-
care, as well as complex treatments and their clinical monitor-
ing, in addition to family/work commitments [28].
The current wide range of Ig presentations, including
IVIG, SCIG, and fSCIG, should lend itself to an enhanced
capacity to tailor treatment to individual patient features and
preferences [14, 15]. This should improve outcomes in the
treatment ofCVIDwith Ig, given its life-long administration,
as several factors may impact on replacement therapies.
These include the route and setting of administration, as
assessed in our study [16, 17]. The groups under different
IgRT were homogeneous in terms of frequency of CVID-
associated conditions and, as already shown [29], no differ-
encewasobservedon the IgRTefficacy in termsof severe and
mild infectious episodes and hospital admissions among dif-
ferent Ig formulations. It has been suggested that in case of
equivalent safety and efficacy of different treatments, clini-
cians should take in account patient’s preference, to ensure
optimal treatment adherence and ultimately get better pa-
tient’s satisfaction [30]. In addition, other factors might in-
fluence the choice of treatment, including recipients’ past
experience, perceived current disease status, and therapy
administration-related factors [31]. In our setting,we record-
ed that younger andGHQ-negative patients preferred fSCIG,
whereas older andGHQ-positive patients, with a longer clin-
ical history, preferred IVIG. This was possibly since in Italy
IVIG is administered entirely in a hospital setting, allowing
to a more frequent contact between patients and care givers.
Young patients without problems of anxiety/depression
more easily accepted the home setting and preferred the
hyaluronidase-facilitated administration that allows a low
number of monthly administrations [32]. In this study, we
also included a group of Bdifficult patients^ requiring both
IVIG and SCIG replacement. These patients displayed a se-
vere phenotype, with a high rate of CVID-related complica-
tions, such as COPD, bronchiectasis, and enteropathy. For
these patients, Ig treatmentmodalitymainly reflected amed-
ical decision based on their poor clinical status and on diffi-
culties inmaintaining IgG trough levels byother schedulesof
administration. It is difficult to speculate on this group, be-
cause of their small number. However, despite of higher rate
of infections and the combined route of administration, these
patients reported CVID_QoL score similar to the other
groups.
A better self-reported HRQoL has been described among
patients who switched from IVIG to SCIG self-infusions at home
[33–35], even though this improvement seems to be largely re-
lated to a switch to home-therapy rather to the SCIG therapy
itself [36–38]. Moreover, several studies evaluating health eco-
nomics in SCIG and IVIG therapy reported that SCIG was a
more cost-effective modality, mainly through the reduction of
productivity loss and days in hospital [33, 39–42]. On the other
hand, in previous studies analyzing HRQoL after shifting from
IVIG to SCIG, it was demonstrated that elderly patients’ ap-
proach to SCIG home therapy could be limited by several factors,
including the perception of inconvenience of time consumed
with self-administration, the aversion to undertake subcutaneous
self-injection, or by the anxiety of possible adverse reactions at
home [43]. This was confirmed also by our study where older
patients still preferred the IVIG treatment.
A limitation of our study is that, at present, the CVID_QoL
questionnaire has only been validated in an Italian context. An
US English version has been also provided by the Texas
Children Hospital group [10]. Study on translation and
cross-cultural validation is currently ongoing in several lan-
guages, including UK and US English, Deutsch, Dutch,
Spanish, Portuguese, Persian, Norwegian, and Greek. A sec-
ond limitation is the lack of longitudinal data on HRQoL of
patients who changed their IgRT.
Independently from the IgRT schedule of administration,
the psychological status of participants was in general highly
compromised, with very high percentages of positive cases by
the GHQ-12 assessment. Moreover, the GHQ-12 positive sta-
tus has been here identified as a major factor impacting on
answers to treatment-related CVID QoL items. This con-
firmed our previous data on a link between GHQ-12 and
HRQoL deteriorations [8, 9]. These data further stress the
necessity to monitor the psychological status in CVID, in or-
der to undertake measures to afford anxiety and depression.
The strong impact of psychological status on the burden of
treatment underlines the need to include instruments address-
ing the psychological status of patients before drawing any
conclusion on the impact of IgRT on HRQoL.
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